

ANTIGENICS INC /DE/  
Form S-8 POS  
June 12, 2003

As filed with the Securities and Exchange Commission on June 11, 2003

Registration No. 333-40442

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

POST-EFFECTIVE AMENDMENT NO. 1 TO  
FORM S-8  
REGISTRATION STATEMENT  
UNDER  
THE SECURITIES ACT OF 1933

---

**ANTIGENICS INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
State or other jurisdiction  
of incorporation or organization)

**06-1562417**  
(I.R.S. Employer  
Identification No.)

**Antigenics Inc.**  
**630 Fifth Avenue, Suite 2100**  
**New York, NY 10111**  
(Address of principal executive offices, including zip code)

---

**1999 EQUITY INCENTIVE PLAN**

(Full title of the plan)

**Garo H. Armen, Ph.D**  
**Antigenics Inc.**  
**630 Fifth Avenue, Suite 2100**  
**New York, NY 10111**  
**212-994-8200**  
(Name, address and telephone number, including area code, of agent for service)

---

**Please send copies of all communications to:**

**Paul M. Kinsella, Esq.**  
**Ropes & Gray**  
**One International Place**  
**Boston, MA 02110**  
**617-951-7000**  
**617-951-7050 (facsimile)**

---

<i>Title of Each Class of Securities to be Registered</i>	<i>Amount to be Registered</i>	<i>Proposed Maximum Offering Price Per Share(1)</i>	<i>Proposed Maximum Aggregate Offering Price(1)</i>	<i>Amount of Registration Fee</i>
---	--------------------------------	---	---	---------------------------------------

---

Edgar Filing: ANTIGENICS INC /DE/ - Form S-8 POS

Common Stock, \$0.01 par value per share	1,200,000 shares(2)	\$14.94	\$17,928,000	\$1,450
---	---------------------	---------	--------------	---------

---

- (1) Pursuant to Rules 457(c) and 457(h)(1) under the Securities Act of 1933, the proposed maximum offering price per share and the maximum aggregate offering price for the shares have been calculated solely for the purpose of computing the registration fee on the basis of the average high and low prices of the Common Stock as reported by the Nasdaq National Market on June 6, 2003 to be \$15.78 and \$14.10, respectively.
  - (2) Pursuant to Rule 416(a) under the Securities Act of 1933, this registration statement also covers such additional shares of Common Stock as may be issued to prevent dilution from stock splits, stock dividends and similar transactions.
-

Explanatory Note

The Registrant hereby amends its Registration Statement on Form S-8 (File No. 333-40442) filed with the Securities and Exchange Commission on June 29, 2000, which is incorporated herein by reference, to increase the number of shares of the Registrant's Common Stock available for issuance under the Antigenics Inc. 1999 Equity Compensation Plan (the Plan) by 1,200,000 shares so that a total of 6,000,000 shares will be available under the Plan.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on this 11th day of June, 2003.

ANTIGENICS INC.

By: /s/ Garo H. Armen, Ph.D.

Name: Garo H. Armen, Ph.D.

Title: Chief Executive Officer and Chairman of the Board

\* \* \* \*

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated as of June 11, 2003.

**Signature**

**Title**

/s/ Garo H. Armen, Ph.D.

Chief Executive Officer and Chairman of the  
Board of Directors  
(Principal Executive Officer)

Garo H. Armen, Ph.D.

/s/ Jeffrey Clark

Chief Financial Officer  
(Principal Financial Officer  
and Principal Accounting Officer)

Jeffrey Clark

\*

Director

Noubar Afeyan, Ph.D

/s/ Frank AtLee

Director

Frank AtLee

\*

Director, Vice Chairman of the Board

Gamil de Chadarevian

/s/ Tom Dechaene

Director

Tom Dechaene

/s/ Margaret Eisen

Director

Margaret Eisen

/s/ Wadih Jordan

Director

Wadih Jordan

/s/ Mark Kessel Director

Mark Kessel

\*

Director

Pramod Srivastava

\* By: /s/ Garo H. Armen, Ph.D.

Garo H. Armen, Ph.D.  
Attorney-in-Fact

---

**EXHIBIT INDEX**

- 4.1 Antigenics Inc. Amendment No. 1 to 1999 Equity Incentive Plan.
- 5.1 Opinion of Ropes & Gray LLP.
- 23.1 Consent of KPMG LLP.
- 23.2 Consent of Ropes & Gray LLP (included in the opinion filed as Exhibit 5.1).
- 24.1 Powers of Attorney (previously filed in Part II of the Form S-8 dated June 29, 2000, File No. 333-40442).